Millions of people throughout the world are affected by chronic hepatitis C, which, if left untreated, can frequently result in serious liver issues. However, the landscape of hepatitis C therapy has changed dramatically in recent years as a result of the creation and use of direct-acting antiviral (DAA) medicines.
